PLASMALYTE

This brand name is authorized in Estonia, Finland, France, Lithuania, New Zealand, Poland.

Active ingredients

The drug PLASMALYTE contains a combination of these active pharmaceutical ingredients (APIs):

1	Sodium chloride UNII 451W47IQ8X - SODIUM CHLORIDE
	Sodium chloride is the principle salt involved in maintaining the osmotic tension of blood and tissues. Changes in osmotic tension influence the movement of fluids and diffusion of salts in cellular tissue.
	Read more about Sodium chloride
2	Potassium chloride UNII 660YQ98I10 - POTASSIUM CHLORIDE
	Potassium plays a vital physiological role in maintenance of normal electrical excitability of nerve and muscle. It is also important in the genesis and correction of imbalances of acid-base metabolism.
	Read more about Potassium chloride
3	Magnesium chloride UNII 02F3473H9O - MAGNESIUM CHLORIDE
	Read more about Magnesium chloride
4	Sodium acetate UNII 4550K0SC9B - SODIUM ACETATE
	Read more about Sodium acetate
5	Sodium gluconate UNII R6Q3791S76 - SODIUM GLUCONATE
	Read more about Sodium gluconate

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
B05BB01	Electrolytes	B Blood and blood forming organs → B05 Blood substitutes and perfusion solutions → B05B I.V. solutions → B05BB Solutions affecting the electrolyte balance
Discover more medicines within B05BB01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1182822, 1182855, 1182866
FI	Lääkealan turvallisuus- ja kehittämiskeskus	027505, 145648
FR	Base de données publique des médicaments	64090327
LT	Valstybinė vaistų kontrolės tarnyba	1019784, 1019785
NZ	Medicines and Medical Devices Safety Authority	1984
PL	Rejestru Produktów Leczniczych	100158360